side effects glp 1 agonist Your guide to GLP-1 Clinical Recommendations to Manage Gastrointestinal
Description
The progression from single to dual to triple agonism has produced measurable advances in clinical research outcomes, and the category continues to evolve as additional compounds enter clinical development
Other ASCO-presented research found that people with stage I, II, or III lung, breast, colorectal, or liver cancer who took a GLP-1 drug were less likely to progress to stage IV disease than those who did not take one
Given unequal payer coverage, the income also directly reduces GLP-1 access due to the inability to afford high co-payments or self-payment
doi: 10.1016/j.drudis.2021.04.025 [DOI] [PubMed] [Google Scholar] 188
The glucagon component adds its own gastrointestinal effects on top of the GLP-1 and GIP effects
It is possible that the anti-inflammatory CRP reductions observed in the STEP and SELECT trials require the full doses used in those studies
